Literature DB >> 8957573

Cotrifazid--an agent against malaria.

E Freerksen1, E W Kanthunkumva, A R Kholowa.   

Abstract

Following the brief information on a new malaria treatment with the fixed multiple combination Cotrifazid (rifampicin+isoniazid+sulfamethoxazole+trimethoprim) in Chemotherapy [1995;41:396-398], very good results are reported for the treatment of 61 patients with various forms of malaria. The tolerance was found to be good. Some relevant fundamental considerations (chemoresistance, synergism/antagonism, fixed multiple combination, switching from monotherapy to combination therapy) and the implementation of the principle of a "multidisease therapy' are discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957573     DOI: 10.1159/000239472

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  3 in total

1.  In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron.

Authors:  B Pradines; C Rogier; T Fusai; J Mosnier; W Daries; E Barret; D Parzy
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Rifampicin/Cotrimoxazole/Isoniazid versus mefloquine or quinine + sulfadoxine- pyrimethamine for malaria: a randomized trial.

Authors:  Blaise Genton; Ivo Mueller; Inoni Betuela; Gerard Casey; Meza Ginny; Michael P Alpers; John C Reeder
Journal:  PLoS Clin Trials       Date:  2006-12-22

Review 3.  Repurposing Drugs to Fight Hepatic Malaria Parasites.

Authors:  Diana Fontinha; Isabel Moules; Miguel Prudêncio
Journal:  Molecules       Date:  2020-07-28       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.